Buprenorphine induces ceiling in respiratory depression but not in analgesia
Top Cited Papers
- 1 May 2006
- journal article
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 96 (5), 627-632
- https://doi.org/10.1093/bja/ael051
Abstract
We measured the effect of two weight adjusted i.v. doses (0.2 mg per 70 kg and 0.4 mg per 70 kg) of the potent opioid buprenorphine on analgesia and respiratory depression in healthy volunteers. The aim of the study was to compare buprenorphine's behaviour with respect to the occurrence of ceiling (or apparent maximum) in these typical micro-opioid protein-(MOP) receptor effects. Ten subjects (5 males) received 0.2 mg per 70 kg, 10 others (5 males) 0.4 mg per 70 kg i.v. buprenorphine. Steady-state inspired minute ventilation at a fixed end-tidal Pco(2) of 7 kPa was measured before drug infusion and at regular intervals after drug infusion. Experimental pain was induced using transcutaneous electrical stimulation and a gradually increasing current. Pain tolerance was measured at regular intervals before and after drug infusion. The studies lasted 8 h. After infusion of the drug ventilation showed a rapid decline and reached peak depression between 150 and 180 min after drug administration. This effect was dose-independent with respect to timing and magnitude. At peak respiratory depression minute ventilation was 13.1 (sd 1.8) litre min(-1) in the 0.2 mg group vs 12.0 (sd 1.3) litre min(-1) in the 0.4 mg group (n.s.). At buprenorphine 0.2 mg a small short-lived analgesic effect was observed with a maximum increase in pain tolerance current of 6.7 (sd 2.8) mA occurring at 75 min after drug administration. Peak analgesic effect was 29% above baseline current. In contrast, buprenorphine 0.4 mg caused a large and long-lived analgesic effect with a maximum increase in pain tolerance current of 23.8 (sd 7.4) mA occurring at 130 min after drug administration. Peak analgesic effect was 160% above baseline current (0.4 vs 0.2 mg, P<0.01). While buprenorphine's analgesic effect increased significantly, respiratory depression was similar in magnitude and timing for the two doses tested. We conclude that over the dose range tested buprenorphine displays ceiling in respiratory effect but none in analgesic effect.Keywords
This publication has 20 references indexed in Scilit:
- Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and ratsBritish Journal of Anaesthesia, 2005
- Morphine Side Effects in β-Arrestin 2 Knockout MicePublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2005
- Transduction of Receptor Signals by ß-ArrestinsScience, 2005
- Broad analgesic profile of buprenorphine in rodent models of acute and chronic painEuropean Journal of Pharmacology, 2005
- Pharmacokinetic-Pharmacodynamic Modeling of Morphine-6-glucuronide-induced Analgesia in Healthy VolunteersAnesthesiology, 2004
- III. Old dog'new (ma)trix † †Declaration of interest. Dr Collett was a member of the Transtec Advisory Board (two Meetings) organised by Napp Pharmaceuticals and has been in receipt of three travel grants from that company over the last 5 years. Dr Budd was a member of the Transtec Advisory Boards of Napp Pharmaceuticals and Grunenthal GmbH and has received lecture and travel expenses from both companies.British Journal of Anaesthesia, 2003
- Sex Differences in Morphine AnalgesiaAnesthesiology, 2000
- Enhanced Morphine Analgesia in Mice Lacking β-Arrestin 2Science, 1999
- Hypercapnia depresses nociception: endogenous opioids implicatedBrain Research, 1990
- THE ANIMAL PHARMACOLOGY OF BUPRENORPHINE, AN ORIPAVINE ANALGESIC AGENTBritish Journal of Pharmacology, 1977